PARP1 and breast carcinoma: This mechanism has been validated in clinical settings, with FDA-approved PARP inhibitors including olaparib, rucaparib, niraparib, and talazoparib demonstrating significant survival benefits for patients with advanced ovarian and breast cancers [41].